Newly identified biomarkers help predict outcome in idiopathic pulmonary fibrosis

A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational Medicine.

IPF causes progressive scarring of the lungs, leading to cough, shortness of breath, and potentially death. In most cases, the cause cannot be identified, and there is no cure other than a . While some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.

The researchers' goal was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.

Using two cohorts of patients, the researchers from Yale, University of Chicago, and University of Pittsburgh analyzed the expression of the genes in the whole genome of patients with IPF, and identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes—CD28, ICOS, LCK, and ITK—predicted shorter survival time in patients with IPF.

The research team believes discovery of these biomarkers will help physicians better predict disease presence, severity, and prognosis in IPF patients. "Given the fact that is the only therapy that has shown to improve survival in IPF, our test could allow physicians to refer IPF patients for lung transplant at the right time—not too late and not too early," said senior and corresponding author Naftali Kaminski, M.D., professor and chief of pulmonary, critical care, and sleep medicine at Yale School of Medicine.

This video is not supported by your browser at this time.
John Morthanos, a patient with IPF who has undergone a lung transplant, describes his experience with the disease and the impact a blood test will have. Credit: Mathur, A. Herazo-May, J. Kaminski, N. Herzog, E. - Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine

Right now, at least six drugs are being studied for IPF. First author Jose Herazo-Maya of Yale School of Medicine said that one of the study's major impacts would be on drug studies. "Current drug studies do not address the variability in outcomes of IPF patients," he said. "Our findings may help investigators target who are more likely to progress and improve."

The decreased genes that predicted shorter survival time were mostly related to immune activation. Author Imre Noth, leader of the University of Chicago team, said, "Our result may also shed light on disease mechanisms, by supporting the emerging notion that aberrant immunity may play a role in IPF."

More information: "Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis," by J.D. Herazo-Maya et al. Science Translational Medicine, 2013.

Related Stories

Gene study helps understand pulmonary fibrosis

Apr 16, 2013

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that ...

Finding cellular causes of lung-hardening disease

Sep 17, 2013

(Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing ...

Recommended for you

Recorded Ebola deaths top 7,000

20 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.